李 歆,袁 霞

类风湿关节炎（rheumatoid arthritis，RA）是一种常见的以进行性关节破坏为特征的慢性炎症性自身免疫病。RA还可引起关节外表现，其中心血管疾病（cardiovascular disease，CVD）的发病率和死亡率明显升高。由于老年患者更多合并症、年龄相关性免疫衰老等危险因素的存在，老年RA的相关研究逐渐显现。本文主要总结了老年发病RA的常用药物对心血管系统的影响，以期为临床应用提供参考依据。

老年发病类风湿关节炎；心血管疾病；治疗

[1] SMOLEN J S,ALETAHA D,MCINNES I B.Rheumatoid arthritis[J].Lancet,2016,388(10055): 2023-2038. [2] 曾小峰,朱松林,谭爱春,等.我国类风湿关节炎疾病负担和生存质量研究的系统评价[J].中国循证医学杂志,2013,13(3):300-307. [3] SERHAL L,LWIN M N,HOLROYD C,et al.Rheumatoid arthritis in the elderly:Characteristics and treatment considerations[J]. Autoimmun Rev,2020,19(6):102528. [4] 陈璐,秦明照,王宁.老年人群心血管疾病的健康管理及预防[J].中华老年多器官疾病杂志,2018,17(12):956-960. [5]张榕,吴春玲,李舒帆,等.雷公藤多甙联合来氟米特治疗老年活动性类风湿关节炎的疗效[J].中国老年学杂志,2011,31(12):2194-2196. [6] AKRAM M,DANIYAL M,SULTANA S,et al.Traditional and modern management strategies for rheumatoid arthritis[J].Clin Chim Acta, 2021,512:142-155. [7] LUNDBERG T R,HOWATSON G.Analgesic and anti-inflammatory drugs in sports:Implications for exercise performance and training adaptations[J].Scand J Med Sci Sports,2018,28(11):2252-2262. [8] CANNON C P,CURTIS S P,FITZGERALD G A,et al.Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term(MEDAL)programme:a randomised comparison[J].Lancet,2006,368(9549):1771-1781. [9] SOUBRIER M,ROSENBAUM D,TATAR Z,et al.Vascular effects of nonsteroidal antiinflammatory drugs[J].Joint Bone Spine, 2013,80(4):358-362. [10] ARTS E E,FRANSEN J,den BROEDER A A,et al.The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients[J].Ann Rheum Dis,2015,74(6):998-1003. [11] BRESALIER R S,SANDLER R S,QUAN H,et al.Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial[J].N Engl J Med,2005,352(11):1092-1102. [12] 张荩元,詹琪,汪津.非甾体抗炎药使用与心血管疾病风险因素关联的研究进展[J].生物化工,2024,10(03):164-172. [13] Neeck G.Fifty years of experience with cortisone therapy in the study and treatment of rheumatoid arthritis[J].Ann N Y AcadSci, 2002,966(1):28-38. [14] REVOLLO J R,CIDLOWSKI J A.Mechanisms generating diversity in glucocorticoid receptor signaling[J].Ann N Y Acad Sci, 2009,1179:167-178. [15] NIEMAN L K,BILLER B M,FINDLING J W,et al.The diagnosis of Cushing's syndrome:an Endocrine Society Clinical Practice Guideline[J].J Clin Endocrinol Metab,2008,93(5):1526-1540. [16] AJEGANOVA S,ANDERSSON M L,FROSTEGARD J,et al.Disease factors in early rheumatoid arthritis are associated with differential risks for cardiovascular events and mortality depending on age at onset:a 10-year observational cohort study[J].J Rheumatol, 2013,40(12):1958-1966. [17] TAKAI C,KOBAYASHI D,ITO S,et al.[The treatment of patients with elderly-onset rheumatoid arthritis at Niigata Rheumatic Center][J].Nihon Ronen Igakkai Zasshi,2018,55(2):251-258. [18] 杨晓倩,秦莉,张艺文,等.糖皮质激素与心血管疾病[J].心血管病学进展,2020,41(04):404-407. [19] RIDKER P M,EVERETT B M,PRADHAN A,et al.Low-Dose Methotrexate for the Prevention of Atherosclerotic Events[J].N Engl J Med,2019,380(8):752-762. [20] JOHNSON T M,SAYLES H R,BAKER J F,et al.Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritis[J].Ann Rheum Dis,2021,80(11):1385-1392. [21] WIDDIFIELD J,ABRAHAMOWICZ M,PATERSON J M,et al.Associations Between Methotrexate Use and the Risk of Cardiovas- cular Events in Patients with Elderly-onset Rheumatoid Arthritis[J].J Rheumatol,2019,46(5):467-474. [22] CHEN L J,ZHOU Y J,WEN Z H,et al.Efficacy and safety of iguratimod combined with methotrexate vs.methotrexate alone in rheumatoid arthritis:A systematic review and meta-analysis of randomized controlled trials[J].Z Rheumatol,2021,80(5):432-446 [23] BROWN P M,PRATT A G,ISAACS J D.Mechanism of action of methotrexate in rheumatoid arthritis,and the search for biomarkers[J]. Nat Rev Rheumatol,2016,12(12):731-742. [24] PENN S K,KAO A H,SCHOTT L L,et al.Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus[J].J Rheumatol,2010,37(6):1136-1142. [25] RIGAUDIERE F,INGSTER-MOATI I,HACHE J C,et al.[Up-dated ophthalmological screening and follow-up management for long-term antimalarial treatment][J].J Fr Ophtalmol,2004,27(2):191-199. [26] JANG C H,CHOI J H,BYUN M S,et al.Chloroquine inhibits production of TNF-alpha,IL-1beta and IL-6 from lipopolysaccharide- stimulated human monocytes/macrophages by different modes[J].Rheumatology(Oxford),2006,45(6):703-710. [27] SHUKLA A M,BOSE C,KARADUTA O K,et al.Impact of Hydroxychloroquine on Atherosclerosis and Vascular Stiffness in the Presence of Chronic Kidney Disease[J].PLoS One,2015,10(9):e139226. [28] 苏建玲,李洋.类风湿关节炎治疗药物对心血管病变影响的研究进展[J].中华老年多器官疾病杂志,2018,17(09):713-716. [29] BAKER J F,SAUER B,TENG C C,et al.Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis Is Associated With Changes in Blood Pressure[J].J Clin Rheumatol,2018,24(4):203-209. [30] Suissa S,Bernatsky S,Hudson M.Antirheumatic drug use and the risk of acute myocardial infarction[J].ArthritisRheum, 2006,55(4):531-536. [31] JIANG X,WANG W,LEI L,et al.Antirheumatic drug leflunomide attenuates atherosclerosis by regulating lipid metabolism and endothelial dysfunction via DHODH/AMPK signaling pathway[J].Int J Biol Sci,2024,20(10):3725-3741. [32] PAVLOV-DOLIJANOVIC S,BOGOJEVIC M,NOZICA-RADULOVIC T,et al.Elderly-Onset Rheumatoid Arthritis:Characteristics and Treatment Options[J].Medicina(Kaunas),2023,59(10). [33] YUN H,XIE F,DELZELL E,et al.Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare[J].Arthritis Rheumatol,2016,68(1):56-66. [34] 胡娣萍,黎艳红,刘毅.生物制剂治疗RA对心血管风险影响的研究进展[J].医学研究杂志,2021,50(05):7-10. [35] XIE W,HUANG Y,XIAO S,et al.Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis:systematic review and meta-analysis of randomised controlled trials[J].Ann Rheum Dis,2019,78(8):1048-1054. [36] KUME K,AMANO K,YAMADA S,et al.Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis:a cohort study[J].Rheumatol Int,2017,37(12):2079-2085. [37] 马林霄,吕倩,邵平,等.托法替布治疗老年类风湿关节炎的疗效及安全性[J].中外医疗,2023,42(36):85-88. [38] MUNOZ-BARRERA L,PEREZ-SANCHEZ C,ORTEGA-CASTRO R,et al.Personalized cardiovascular risk assessment in Rheumatoid Arthritis patients using circulating molecular profiles and their modulation by TNFi,IL6Ri,and JAKinibs[J].Biomed Pharmacother, 2024,173:116357.

点击下载PDF